JUPITER NEUROSCIENCES INC

Jupiter Neurosciences is a clinical-stage pharmaceutical company whose business model depends on animal testing for drug development. The company’s primary drug candidate, a resveratrol formulation for rare neurological disorders, has been advanced through preclinical studies that utilize animal subjects to demonstrate safety and pharmacokinetics. This reliance on animal models is a core, non-incidental component of its research and development pipeline.

While specific details on the scale or conditions of Jupiter Neurosciences' animal testing are not publicly disclosed in the gathered evidence, the company’s operational focus places it within a pharmaceutical sector where animal use is standard. A 2025 audit report on U.S. laboratories documented widespread animal welfare violations and systemic suffering, illustrating the industry context in which such testing occurs. The absence of a publicly available animal welfare policy or commitment to alternative testing methods further situates the company within this exclusion category.